ERBB2 S310Y

CI-VAR-00004048Explore in graph →NP_004439.2:p.Ser310TyrNM_004448.4:c.929C>AClinVar 376188 CIViC 1215

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB2 S310Y	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	2	submitted	EID12232 In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC	civic
Malignant Lung Neoplasm1
ERBB2 S310Y	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID11489 Cell proliferation analysis of NIH 3T3 cells harboring the S310Y variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.